Cost and cost-effectiveness of dolutegravir-based antiretroviral regimens: an economic evaluation of a clinical trial-Reference-Cited by-同舟云学术

Cost and cost-effectiveness of dolutegravir-based antiretroviral regimens: an economic evaluation of a clinical trial

Published:2021-12-15 Issue:Supplement 2 Volume:35 Page:S173-S182
ISSN:0269-9370
Container-title:AIDS
language:en
Short-container-title:

Author:

Jamieson Lise,Serenata Celicia,Makhubele Lebogang,Sokhela Simiso,Mashabane Nkuli,Akpomiemie Godspower,Johnson Leigh F.,Venter Willem D.F.,Meyer-Rath Gesine

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Infectious Diseases,Immunology,Immunology and Allergy

Reference28 articles.

1. Has the time come to abandon efavirenz for first-line antiretroviral therapy?;Raffi;J Antimicrob Chemother,2014

2. Dolutegravir based antiretroviral therapy compared to other combined antiretroviral regimens for the treatment of HIV-infected naive patients: a systematic review and meta-analysis;Cruciani;PLoS One,2019

3. Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort;Mondi;J Int AIDS Soc,2019

4. Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis;Kanters;Lancet HIV,2016

5. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection;Walmsley;N Engl J Med,2013

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-Effectiveness of Dolutegravir Compared With Efavirenz for Prevention of Perinatal Transmission in Women Presenting With HIV in Late Pregnancy in Uganda;Value in Health Regional Issues;2024-11

2. Virologic Failure and Drug Resistance After Programmatic Switching to Dolutegravir-based First-line Antiretroviral Therapy in Malawi and Zambia;Clinical Infectious Diseases;2024-06-07

3. The Cost-Effectiveness of Dolutegravir in Combination with Tenofovir and Lamivudine for HIV Therapy: A Systematic Review;ClinicoEconomics and Outcomes Research;2024-01

4. Improvements in Patient-Reported Outcomes Following Initiation of Dolutegravir-Based or Low-Dose Efavirenz-Based First-Line Antiretroviral Therapy: A Four-Year Longitudinal Analysis in Cameroon (NAMSAL ANRS 12313 Trial);JAIDS Journal of Acquired Immune Deficiency Syndromes;2023-11-01

5. Limited emergence of resistance to integrase strand transfer inhibitors (INSTIs) in ART-experienced participants failing dolutegravir-based antiretroviral therapy: a cross-sectional analysis of a Northeast Nigerian cohort;Journal of Antimicrobial Chemotherapy;2023-06-27